GENE ONLINE|News &
Opinion
Blog

2021-11-24| Trials & Approvals

Takeda’s Livtencity Bags FDA Approval for the Treatment of Post-Transplant Infection

by Joy Lin
Share To

On November 24th, the FDA approved Takeda’s Livtencity (maribavir) for patients with post-transplant cytomegalovirus (CMV) infection, a common complication that is tricky to treat owing to drug resistance. Prior to the approval, the drug had received Orphan Drug Designation from the FDA.

The treatment will be accessible to patients aged 12 and older with a weight of at least 35 kg who have not responded well to existing antiviral treatments such as ganciclovir and valganciclovir.

“Transplant recipients are at a much greater risk for complications and death when faced with a cytomegalovirus infection,” said John Farley, Director of the Office of Infectious Diseases in the FDA’s Center for Drug Evaluation and Research.

“Cytomegalovirus infections that are resistant or do not respond to available drugs are of even greater concern. Today’s approval helps meet a significant unmet medical need by providing a treatment option for this patient population.”

Related Article: Xenotransplantation-A Boon for the Needy or an Ethical Conundrum?

 

A Common and Deadly Infection

CMV, a type of herpes virus, is one of the most common viral infections to affect transplant recipients. Around 16%-56% of solid organ transplant recipients and 30%-70% hematopoietic stem cell recipients get infected. 

While CMV is usually dormant in the body, immunosuppression during transplant surgery may reactivate it. Reactivation could cause loss of the transplanted organ or even death.

Related Article: Takeda Inks $3.6 Billion Deal with Poseida to Advance Non-Viral Gene Therapies and Overcome Safety Issues

 

Livtencity Blocks CMV Replication 

Livtencity blocks viral replication via first-in-class inhibition of human CMV enzyme pUL97. 

The US approval is based on results from the SOLSTICE study, which involved 352 transplant patients with treatment-resistant infection. The Phase 3 trial showed that Livtencity was superior to standard treatments ganciclovir, valganciclovir, foscarnet, and cidofovir. 56% of the 235 patients who received Livtencity had CMV DNA levels below what was measurable, compared to 24% of 117 patients who received one of the assigned antivirals.

The drug is also being investigated in a Phase 3 trial as a first-line treatment of CMV in hematopoietic stem cell transplantation. 

Common side effects of Livtencity included taste disturbance, nausea, diarrhea, vomiting, and fatigue. The drug could antagonize the effects of ganciclovir and valganciclovir, so it is not recommended to use the drugs together. Relapse of CMV could still occur, usually within 4-8 weeks after treatment discontinuation.

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Takeda Collaborates with Immusoft to Advance Treatments in Rare Metabolic Diseases
2022-01-14
FDA Approves Drug for Schizophrenia in Pediatric Patients
2022-01-10
Korro Bio Raises $116 Million for RNA Editing Program
2022-01-06
LATEST
Biotech Showcase 2022: Healing the Psyche with Psychedelia
2022-01-17
Sex Dimorphism in Obesity and the Impact of Estrogen Hormone Therapy on Cardiometabolic Health
2022-01-17
ARM 2022: Industry Briefs on Cell and Gene Therapies
2022-01-17
Study Reveals a Form of Four-Stranded DNA that Links Protein Deficiency and Premature Aging
2022-01-17
Shanghai’s Everest Medicines Licenses Covid-19 Oral Antivirals from Singapore’s National Drug Discovery Platform
2022-01-17
Digital Health Programme to Connect British and Taiwanese Leaders
2022-01-17
Pfizer: Pneumonia Shot Can Be Given with COVID-19 Vaccine in Older Adults
2022-01-16
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!